Across 4 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Corteva news is Slightly Bearish (-10)
on a scale from −100 to +100.
That is down 59 points from the previous 30 days (+49).
📉 Shares fell 24.3% to $9.19 after disappointing earnings and lowered guidance.
💰 Full-year adjusted core profit outlook slashed from $1.3B to $1.1B.
Very Bearish -75
Corteva Inc. (CTVA) Falls Harder Than Wall Street — Here’s Why
AI-generated analysis
Key insights
📉 Corteva Inc. (NYSE:CTVA) shares fell by 24.30 percent to close at $9.19 following the release of disappointing earnings and lowered guidance.
💰 The company slashed its full-year adjusted core profit outlook significantly, reducing the forecast from $1.3 billion to $1.1 billion.
🇧🇷 CEO Luke Kissam warned that Brazil's market conditions deteriorated sharply in Q3, with negative development continuing into the current period.
📉 Net sales for Corteva dropped by 6 percent year-over-year to $2.458 billion during the third quarter of the fiscal year.
💸 The firm widened its net loss by 78.6 percent in Q3, reporting a loss of $568 million compared to $318 million last year.
🌱 Corteva completed the separation of its seed and genetics business into a separate entity called Vylor earlier this year.
📉 A large portion of products sold into the Brazil channel last year did not reach end-users, impacting revenue realization.
📊 Investor sentiment was dampened by the company's cautious outlook regarding future growth prospects for the rest of the year.
📉 Risk factors
📉Corteva Inc. shares fell by 24.30 percent to close at $9.19, reflecting a severe underperformance relative to Wall Street expectations.
💰The company slashed its full-year adjusted core profit outlook from $1.3 billion to $1.1 billion due to deteriorating market conditions.
📉Net sales fell by 6 percent year-over-year to $2.458 billion in the third quarter, indicating a decline in revenue generation.
💸The firm widened its net loss by 78.6 percent to $568 million in Q3 compared to $318 million in the same period last year.
🇧CEO Luke Kissam stated that consumer spending behavior in Brazil is not expected to improve meaningfully in the near term.
📉A significant amount of product sold into the Brazil channel last year did not go to ground, negatively impacting sales performance.
Article
Corteva Inc. (NYSE:CTVA) shares plummeted by 24.30 percent to close at $9.19, driven by a cautious outlook and reduced annual growth guidance for the remainder of the year. The company's stock performance reflects significant investor concern regarding deteriorating market conditions, particularly in Brazil, which has become a major drag on its financial trajectory.
During an earnings call, CEO Luke Kissam highlighted that consumer spending behavior in Brazil is not expected to improve meaningfully in the near term. He noted that a substantial portion of products sold into the Brazilian channel last year failed to reach end-users, exacerbating the company's revenue challenges and contributing to a sharp decline in sales.
Financially, Corteva slashed its full-year adjusted core profit outlook from $1.3 billion to $1.1 billion. In the third quarter, the company widened its net loss by 78.6 percent to $568 million compared to the same period last year, while net sales fell by 6 percent to $2.458 billion, marking a significant downturn in operational performance.
Earlier this year, Corteva completed the separation of its seed and genetics business into a new publicly traded entity named Vylor. Despite this strategic restructuring, the current earnings miss and guidance cut have overshadowed recent corporate developments, leading to a substantial decline in shareholder value.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Corteva Inc. (NYSE: CTVA) announced on June 29, 2026, the intended nine-member board of directors for its future standalone crop protection company, scheduled to separate in the fourth quarter of 2026. Greg Page will serve as independent chair, while Luke Kissam joins as the future CEO and director. The new board blends current Corteva leadership with external industry veterans from companies like Cargill, Evonik, Deere, Dow, Westlake, Siteimprove, Land O'Lakes, and Cummins.
The planned separation aims to create a differentiated, innovation-driven entity focused on crop protection technologies. The new company intends to operate an asset-light model leveraging its technological leadership and first-mover advantage in nature-inspired technologies. While most current directors remain with the parent Corteva entity, four specific members (Karen Grimes, Marcos Lutz, Chuck Magro, and Kerry Preete) will transition to the remaining business.
Management emphasized that the new standalone company will focus on operational efficiency and delivering value through a differentiated product portfolio. The announcement advances the corporate restructuring plan, positioning the crop protection unit as a publicly traded entity with a distinct strategic identity aimed at maximizing productivity for farmers and generating attractive returns for shareholders.
📅 Corteva to spin off crop protection business in Q4 2026.
👥 Nine-member board led by independent chair Greg Page.
🚀 Luke Kissam appointed as future CEO of new entity.
💡 New company adopts asset-light model with nature-inspired innovation.
📈 Stock rose modestly (+1%) on governance news.
📅 Corteva plans to separate its crop protection business into a standalone, publicly traded company in Q4 2026.
👥 A nine-member board has been named for the future entity, led by Greg Page as independent chair.
🚀 Luke Kissam is appointed as the future CEO and director of the new crop protection company.
🔄 Most current Corteva directors remain with the parent company, except four who transition to the remaining business.
💡 The new company will focus on an asset-light operating model and differentiated innovation in crop protection.
🌱 Strategy includes leveraging nature-inspired technologies and first-mover advantages for market differentiation.
📈 Recent stock movement was modest (+1%), suggesting the market is processing specific governance details rather than broad sector shifts.
The announcement confirms a clear timeline (Q4 2026) and defined leadership structure for the spin-off, reducing execution uncertainty regarding the separation plan.
Greg Page, a retired CEO of Cargill, is selected as independent chair, bringing significant operational expertise to lead the new entity.
Luke Kissam's appointment as future CEO aligns management directly with the standalone business strategy, ensuring focused leadership post-separation.
The board composition includes high-profile industry leaders from major agricultural and industrial sectors, signaling strong external validation of the company's strategic direction.
Management explicitly commits to an 'asset-light' operating model and leveraging 'nature-inspired technologies,' which could improve margins and drive long-term growth.
Risk Factors
There is a risk that the announcement of the separation could negatively impact the company's ability to retain key personnel or maintain critical relationships with customers and suppliers during the transition.
The restructuring may divert management attention and time away from core operations, potentially affecting short-term execution.
Banque Cantonale Vaudoise significantly increased its stake in Corteva, Inc. (CTVA) by 305.6% during the first quarter, adding 13,797 shares to reach a total holding of 18,311 shares valued at $1.53 million. Several other institutional investors, including JPL Wealth Management and various financial advisors, also established new positions in the stock during the third and fourth quarters, indicating continued institutional interest.
Wall Street analysts have recently upgraded their outlook for Corteva, with Deutsche Bank raising its price target to $100.00, Mizuho increasing its target to $94.00 with an 'outperform' rating, and Royal Bank of Canada adjusting its target to $97.00. The consensus rating among fourteen buy-side analysts is a 'Moderate Buy,' supported by an average price target of $88.81, reflecting positive sentiment regarding the company's financial trajectory.
Corteva reported strong quarterly earnings on May 5th, beating analyst expectations with EPS of $1.50 against a consensus of $1.18 and revenue of $4.91 billion versus an expected $4.64 billion. The company achieved an 11% year-over-year revenue increase, demonstrating robust growth in its agriculture-focused business which combines seed genetics and crop protection technologies.
The stock currently trades with a market capitalization of $55.24 billion and a PE ratio of 48.59, trading above its 50-day moving average of $79.38. The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.07 and recently declared a quarterly dividend of $0.18 per share, providing income to investors while maintaining a sustainable payout ratio of 42.35%.
📈 CTVA stake surged 305.6% to 18,311 shares in Q1.
💰 New institutional positions valued $25k-$30k established in Q3/Q4.
🚀 Corteva beat Q1 earnings with $1.50 EPS vs $1.18 consensus.
💵 Revenue hit $4.91 billion, up 11% year-over-year.
🛡️ Strong balance sheet shows 0.07 debt-to-equity and 1.47 current ratio.
📈 Banque Cantonale Vaudoise lifted its CTVA stake by 305.6% in Q1, acquiring an additional 13,797 shares to hold a total of 18,311 shares.
💰 Multiple institutional investors including JPL Wealth Management and Bank of Jackson Hole Trust established new positions valued between $25,000 and $30,000 in Q3 and Q4.
📊 Deutsche Bank raised its price target to $100.00, while Mizuho and Royal Bank of Canada also increased targets with 'outperform' ratings.
🚀 Corteva beat Q1 earnings estimates significantly, reporting $1.50 EPS compared to the consensus of $1.18.
💵 Revenue reached $4.91 billion in the quarter, representing an 11% year-over-year increase over analyst expectations of $4.64 billion.
📉 The stock trades at a PE ratio of 48.59 with a market capitalization of $55.24 billion and a beta of 0.57.
💰 A quarterly dividend of $0.18 per share was paid on June 15th, resulting in an annualized yield of 0.9%.
🛡️ The company maintains a strong balance sheet with a debt-to-equity ratio of 0.07 and a current ratio of 1.47.
🌱 Corteva focuses on seed genetics and crop protection, having separated from DowDuPont in mid-2019 to become an independent global agriculture company.
📅 Analysts forecast FY 2026 EPS between $3.45 and $3.70, with the current year consensus estimate at $3.72.
Bullish Signals
Banque Cantonale Vaudoise stake rose 305.6% in Q1.
Deutsche Bank raised target to $100.00.
Corteva EPS beat estimates at $1.50 vs $1.18.
Revenue hit $4.91B, up 11% year-over-year.
Low debt-to-equity ratio of 0.07 ensures stability.
Bullish Signals
Banque Cantonale Vaudoise increased its stake by 305.6% in Q1, signaling strong institutional confidence in the company's long-term prospects.
Deutsche Bank raised its price target to $100.00, Mizuho set a target of $94.00 with an 'outperform' rating, and Royal Bank of Canada adjusted its target to $97.00.
Corteva reported EPS of $1.50, significantly beating the consensus estimate of $1.18 by $0.32.
Revenue of $4.91 billion exceeded analyst expectations of $4.64 billion, driven by an 11% year-over-year growth rate.
The company maintains a very low debt-to-equity ratio of 0.07 and a current ratio of 1.47, indicating strong liquidity and financial stability.
Fourteen analysts have issued Buy ratings on the stock, contributing to a consensus 'Moderate Buy' rating with an average target price of $88.81.
Assenagon Asset Management S.A. significantly reduced its position in Corteva, Inc. (NYSE:CTVA) by 44.7% during the first quarter, selling 403,529 shares to hold a remaining stake of 499,517 shares valued at approximately $41.8 million according to recent SEC filings.
Despite this notable decrease by one major institutional holder, several other wealth management firms and hedge funds established new positions in the stock during the third and fourth quarters, with stakes ranging from roughly $25,000 to $30,000 each, indicating continued institutional interest.
Analyst sentiment remains broadly positive with major financial institutions including Barclays, Mizuho, Morgan Stanley, and Goldman Sachs recently raising their price targets for Corteva between $84.00 and $96.00, while maintaining 'overweight' or 'buy' ratings.
Corteva continues to operate as an independent global agriculture company with a market capitalization of $54.52 billion, trading near its 52-week high, and recently paid a quarterly dividend yielding 0.9% to shareholders of record.
📉 Assenagon sold 400k shares, dropping stake by 44.7%.
💰 Remaining stake valued at $41.8 million.
🏦 Institutional investors own 81.54% of outstanding stock.
📊 Stock trades at $81.51 with $54.5 billion market cap.
🔭 Analysts raised targets to $91-$96 with buy ratings.
📉 Assenagon Asset Management S.A. decreased its Corteva holdings by 44.7% in Q1, selling over 400,000 shares.
💰 The remaining Assenagon stake is valued at $41,815,000 as of the latest SEC filing.
📈 Multiple wealth management firms opened new positions totaling approximately $139,000 in Q3 and Q4.
🏦 Institutional investors collectively own 81.54% of Corteva's outstanding stock.
📊 CTVA stock is trading at $81.51 with a market cap of $54.52 billion.
💵 The company recently paid a $0.18 per share dividend, annualizing to a 0.9% yield.
🔭 Barclays raised its price target from $84.00 to $91.00 with an 'overweight' rating.
🎯 Goldman Sachs increased its target to $96.00 and maintains a 'buy' rating.
📉 The stock trades at a P/E ratio of 47.95 with a beta of 0.57.
🌱 Corteva focuses on seed genetics, crop protection chemistries, and digital tools for farmers.
Bullish Signals
Major analysts raised price targets for Corteva.
Stock trades near 52-week high of $85.63.
Institutional ownership remains robust at 81.54%.
Current ratio is 1.47 with low debt.
Risk Factors
Assenagon Asset Management cut holdings by nearly half.
High P/E ratio of 47.95 suggests elevated valuation.
Bullish Signals
Major analysts including Barclays, Mizuho, Morgan Stanley, and Goldman Sachs have recently raised their price targets for Corteva, signaling confidence in future performance.
The stock is trading near its 52-week high of $85.63, suggesting strong recent market momentum.
Institutional ownership remains robust at 81.54%, indicating sustained interest from large investors despite individual position adjustments.
Corteva maintains a healthy balance sheet with a current ratio of 1.47 and a low debt-to-equity ratio of 0.07.
Risk Factors
A significant institutional investor, Assenagon Asset Management S.A., reduced its position by nearly half in the first quarter.
The stock trades at a high P/E ratio of 47.95, which may suggest elevated valuation relative to earnings.
Corteva Inc (CTVA) shares rose approximately 1.51% to $81.38 following a landmark 7-2 U.S. Supreme Court ruling in Monsanto v. Durnell. The high court determined that the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) expressly preempts state-level 'failure to warn' liability claims regarding pesticide labels. Justice Brett Kavanaugh emphasized that because the EPA holds authority over uniform labels, state tort laws cannot enforce additional warning demands, effectively shielding agricultural corporations from a complex patchwork of state litigation.
This legal victory is viewed as a massive catalyst for Corteva and the broader crop protection sector by restoring regulatory clarity and drastically lowering long-term legal liability risks. The ruling establishes an industry-wide precedent that blocks future class-action exposure related to warning labels, providing significant relief to companies like Corteva which operate globally with substantial revenue derived from North America.
Technically, CTVA is trading above its major trend gauges, sitting about 5% above the 20-day simple moving average ($77.54) and roughly 11.6% above the 200-day SMA ($72.92). While the stock maintains a longer-term uptrend supported by a golden cross in February, it faces a short-term speed bump as the 20-day SMA remains below the 50-day SMA. Key resistance is identified at $84.50 near the 52-week high zone of $85.63, with support established around $78.50.
Corteva, spun off from DowDuPont in 2019, plans to split its business by late 2026 into a seeds unit named Vylor and a crop protection business retaining the Corteva name. Currently, seeds generate the majority of profits while crop protection provides the remainder. The company operates globally, making regional planting cycles and input demand critical factors for sentiment alongside the favorable legal environment.
⚖️ Supreme Court rules FIFRA preempts state 'failure to warn' claims against pesticide makers.
🎯 Technical resistance sits at $84.50 with support near $78.50.
🔄 Company plans to spin off seeds business into Vylor by late 2026.
🌾 Seeds generate majority of profits while North America drives half revenue.
🏛️ U.S. Supreme Court ruled 7-2 in Monsanto v. Durnell that FIFRA preempts state-level 'failure to warn' claims against pesticide manufacturers.
⚖️ Justice Brett Kavanaugh affirmed that EPA authority over uniform labels prevents states from enforcing additional warning demands via tort laws.
📈 Corteva shares rose 1.51% to $81.38, trading above the 20-day SMA ($77.54) and 200-day SMA ($72.92).
🛡️ The ruling establishes an industry-wide legal precedent that shields agricultural corporations from costly state-level litigation and class actions.
📉 Technical analysis shows a short-term speed bump as the 20-day SMA remains below the 50-day SMA ($79.42).
🎯 Key resistance is identified at $84.50, just below the 52-week high zone of $85.63.
🔒 Key support is established near $78.50, aligning with the 50-day/100-day moving average area.
🔄 Corteva plans to spin off its seeds business into a new entity named Vylor by late 2026.
🌾 Seeds currently generate the majority of Corteva's profits, while crop protection provides the remainder of revenue.
📊 Benzinga Edge scores rate Corteva quality as Strong (71.62) and value as Neutral (51.05).
📈 MACD momentum indicators show improvement with the histogram positive and MACD above its signal line.
🌍 Approximately half of Corteva's revenue comes from North America, making regional planting cycles vital.
Bullish Signals
Supreme Court ruling preempts state claims, lowering liability risks.
Shares trade 5% above 20-day SMA and 11.6% above 200-day SMA.
MACD above signal line with positive histogram indicates easing downside pressure.
Restores regulatory clarity, shielding companies from complex state litigation.
Strong Benzinga Edge quality score of 71.62 suggests solid business.
Risk Factors
20-day SMA below 50-day SMA hinders quick rallies.
Immediate resistance at $84.50 stalls rebounds near $85.63 high.
Growth score of 39.27 indicates neutral expansion outlook.
Bullish Signals
The Supreme Court ruling provides a massive legal victory by preempting state-level 'failure to warn' claims, drastically lowering long-term liability risks for the crop protection sector.
Corteva shares are trading above major trend gauges, specifically sitting 5% above the 20-day SMA and 11.6% above the 200-day SMA, indicating an intact longer-term uptrend.
Momentum indicators suggest downside pressure is easing with the MACD above its signal line and a positive histogram, signaling buyers are gaining traction.
The decision restores regulatory clarity across the agricultural chemical sector, effectively shielding companies like Corteva from a complex patchwork of state litigation.
Corteva maintains a 'Strong' quality score of 71.62 on the Benzinga Edge model, suggesting solid underlying business quality that can help hold up during market pullbacks.
Risk Factors
Short-term technical structure shows a crossover where the 20-day SMA is below the 50-day SMA, which could act as a speed bump if the stock attempts to rally quickly.
The stock faces immediate resistance at $84.50, located just below the 52-week high zone of $85.63, where rebounds may stall before reaching new highs.
Growth factors are currently rated neutral with a score of 39.27, indicating that price action relies more on execution and cycle tailwinds than rapid expansion.
Corteva Inc. (CTVA) recently announced a multi-year, co-exclusive supply and license agreement with FMC Corporation for rimisoxafen herbicide technology. This partnership covers North and South American markets and includes a $200 million prepurchase payment from Corteva. The deal is designed to provide the company with an additional tool for corn and soybean crop protection, with commercial sales targeted by the end of the decade pending regulatory approvals.
At a current share price of $78.59, Corteva has delivered a 16% year-to-date return and a 41.9% total shareholder return over three years. Analysts estimate a fair value of approximately $90.05 based on earnings and margin expectations, suggesting the stock could be undervalued by roughly 13%. The company's growth narrative relies on advancements in its innovation pipeline, including premium trait launches like Vorceed and PowerCore, expansion into biological products, and gene editing technologies.
Despite the optimistic valuation outlook, investors face specific risks that could unsettle current assumptions. These include competitive pressure from low-cost generic herbicides in the crop protection sector and currency fluctuations in key emerging markets. Additionally, Corteva currently trades at a P/E ratio of 42x, significantly higher than the US Chemicals industry average of 26.5x, which implies that the market expects sustained earnings growth to justify this premium valuation multiple.
🤝 Corteva signs exclusive rimisoxafen deal with FMC for Americas.
💰 $200 million prepurchase payment included in multi-year agreement.
🌱 Herbicide sales target end of decade pending regulatory approval.
⚠️ Faces generic competition and currency risks in emerging markets.
📈 Stock trades at 42x P/E, implying potential 13% undervaluation.
🤝 Corteva signed a multi-year co-exclusive agreement with FMC Corporation for rimisoxafen herbicide technology covering North and South America.
💰 The partnership includes a $200 million prepurchase payment from Corteva to FMC.
🌱 Commercial sales of the new herbicide are targeted by the end of the decade pending regulatory approvals.
📈 Corteva shares have delivered a 16% year-to-date return and a 41.9% total shareholder return over three years.
💵 Analysts estimate a fair value of $90.05, implying the stock is potentially undervalued by approximately 13%.
🧬 Growth strategy includes premium trait launches (Vorceed, PowerCore), biological product expansion, and gene editing.
⚠️ The company faces pressure from low-cost generic competitors in the crop protection market.
💱 Currency swings in key emerging markets pose a risk to revenue stability and margin assumptions.
📊 Corteva trades at a 42x P/E ratio, which is significantly higher than the 26.5x industry average for US Chemicals.
🎯 High valuation implies the market expects earnings growth to justify the premium over sector peers.
Bullish Signals
Secured $200M prepurchase payment from FMC.
Delivered 41.9% total shareholder return in 3 years.
Analysts project fair value of $90.05 vs $78.59 price.
Advancing innovation pipeline with premium trait launches.
Risk Factors
Competitive pressure from low-cost generic herbicides impacts pricing power.
Currency fluctuations in emerging markets risk revenue and margins.
Corteva trades at 42x P/E vs 26.5x industry average.
Bullish Signals
Corteva secured a strategic partnership with FMC Corporation involving a $200 million prepurchase payment, signaling strong demand and financial commitment from partners.
The company has delivered a 16% year-to-date share price return and a 41.9% total shareholder return over the past three years.
Analysts project a fair value of $90.05, suggesting the current stock price of $78.59 may be undervalued by approximately 13%.
Corteva is advancing its innovation pipeline with premium trait launches and gene editing technologies that aim to secure market share and improve product mix.
Risk Factors
The company faces competitive pressure from low-cost generic herbicides in the crop protection sector, which could impact pricing power.
Currency fluctuations in key emerging markets present a risk that could unsettle revenue and margin assumptions used in valuation models.
Corteva trades at a 42x P/E ratio, which is substantially higher than the 26.5x industry average, leaving less room for error if earnings growth slows.
Corteva (CTVA) stock has recently pulled back, trading around $75.71 per share after a 7.9% decline over the past week and an 11.7% drop year-to-date. Despite this short-term weakness, the stock remains up 3.0% over the last year and has delivered significant long-term returns of 36.7% over three years and 84.1% over five years. The article analyzes whether this pullback represents a buying opportunity or a shift in risk perception within the chemicals sector.
A primary valuation metric used is the Discounted Cash Flow (DCF) model, which projects Corteva's future free cash flows out to 2035. Based on trailing twelve-month free cash flow of approximately $2.03 billion and analyst extrapolations reaching $3.89 billion by 2035, the model calculates an intrinsic value of $107.17 per share. This suggests the stock is undervalued by roughly 29.4% relative to its current price.
However, traditional P/E ratio analysis presents a conflicting view. Corteva currently trades at a P/E of 40.44x, which is higher than its proprietary 'Fair Ratio' estimate of 25.49x and above the Chemicals industry average of 28.77x. While this metric indicates the stock might be overvalued on a multiple basis, the article suggests that narrative-based valuation approaches allow investors to reconcile these differing signals by attaching their own growth stories to the financial forecasts.
📉 Shares eased slightly after a 7.9% weekly pullback.
📈 Long-term returns are strong with 36.7% over three years.
💰 Trailing free cash flow reached approximately $2.03 billion.
🔮 DCF projects annual free cash flows to hit $3.89B by 2035.
💵 Intrinsic value of $107.17 implies a 29.4% undervaluation.
📉 Corteva shares have recently eased slightly, trading around $75.71 after a 7.9% pullback over the last week.
📈 Long-term performance remains strong with a 36.7% return over three years and an 84.1% gain over five years.
💰 The company generated trailing twelve-month free cash flow of approximately $2.03 billion.
🔮 DCF projections estimate annual free cash flows will reach about $3.89 billion by the year 2035.
💵 A Discounted Cash Flow model calculates an intrinsic value of $107.17 per share, implying a 29.4% undervaluation.
📊 Corteva currently trades at a P/E ratio of 40.44x, which is higher than its proprietary Fair Ratio of 25.49x.
🏭 The stock's P/E sits above the Chemicals industry average of roughly 28.77x but below the peer group average of 53.67x.
🧠 Simply Wall St introduces a 'Narrative' approach to valuation that allows investors to model different growth scenarios against current prices.
📉 The article notes that Corteva's 1-year return is lagging behind its peers despite the DCF suggesting value.
Bullish Signals
Undervalued by 29.4% with intrinsic value of $107.17.
36.7% return over three years and 84.1% over five.
Trailing twelve-month free cash flow of $2.03 billion.
Future cash flow estimates reach $3.89 billion by 2035.
P/E ratio of 40.44x is lower than peer average.
Risk Factors
Stock P/E of 40.44x exceeds fair estimate of 25.49x.
Valuation multiple of 40.44x is higher than industry average of 28.77x.
Share price declined 11.7% year-to-date and 7.9% last week.
Bullish Signals
The stock is estimated to be undervalued by approximately 29.4% based on a Discounted Cash Flow analysis projecting an intrinsic value of $107.17.
Corteva has demonstrated strong long-term growth with a 36.7% return over the past three years and an 84.1% return over five years.
The company maintains a healthy cash generation profile with trailing twelve-month free cash flow of $2.03 billion.
Future cash flow projections are robust, with estimates reaching $3.89 billion by 2035 according to the model used.
Corteva's P/E ratio of 40.44x is lower than its peer group average of 53.67x, suggesting it may be relatively cheaper compared to direct competitors.
Risk Factors
The stock trades at a P/E ratio of 40.44x, which is significantly higher than the company's proprietary Fair Ratio estimate of 25.49x.
Corteva's current valuation multiple exceeds the Chemicals industry average of roughly 28.77x, indicating potential overvaluation on traditional metrics.
The recent share price has declined by 11.7% year-to-date and 7.9% in the last week, reflecting a short-term pullback.
Corteva Inc. announced plans to cease production activities at its facility in Asturias, Spain, as part of a broader multi-year footprint optimization and productivity initiative. The company stated that the closure is subject to an ongoing consultation process with the applicable works council and union representatives.
As a direct result of this expansion of its restructuring efforts, Corteva has revised its financial outlook for pre-tax restructuring and asset-related charges. The company now expects these costs to range between $750 million and $815 million, representing an increase of $100 million to $115 million from its previous forecast.
The additional costs are primarily attributed to increased severance payments and closure expenses associated with the Spanish site shutdown. This move aligns with a productivity initiative first disclosed at an investor conference in 2024, which originally targeted $300 million in total run-rate productivity savings by next year.
🏭 Corteva ceases Asturias, Spain production for footprint optimization.
💰 Restructuring charges raised to $750-$815 million total.
📈 Additional closure costs add $100-$115 million to charges.
🤝 Closure awaits consultation with local works council and unions.
🎯 Plan targets $300 million annual productivity savings by next year.
🏭 Corteva plans to cease production at its Asturias, Spain facility as part of a multi-year footprint optimization initiative.
💰 The company raised its expected pre-tax restructuring and asset-related charges to between $750 million and $815 million.
📈 This cost increase of $100 million to $115 million is driven by additional severance and closure costs associated with the Spanish site.
🤝 The facility closure is currently subject to a consultation process with the local works council and union representatives.
🎯 The restructuring aligns with a 2024 investor conference disclosure targeting $300 million in total run-rate productivity savings by next year.
Corteva Inc. (CTVA) shares experienced a rally of 2.07%, closing Thursday at $81.01, marking the company's second consecutive day of gains. This performance occurred within a broader market context where major indices posted significant increases; specifically, the S&P 500 Index rose 1.02% to reach 7,209.01, and the Dow Jones Industrial Average climbed 1.62% to close at 49,652.14.
Despite the positive movement in Corteva's stock price and the general bullish sentiment across the market, the company notably underperformed when compared directly to its competitors. The discrepancy between Corteva's gains relative to its peers suggests a divergent trading narrative or investor positioning within the agribusiness sector during this session, even as the broader equities market remained strong.
The data provided is based on intraday information from FACTSET and reflects trades reported through Nasdaq, with a delay of at least 15 minutes for U.S. stock quotes. The report was published by MarketWatch on April 30, 2026, noting that the article content is supported by world-class markets data from Dow Jones and FactSet in partnership with Automated Insights.
📈 CTVA shares rose 2.07% to close at $81.01.
📊 S&P 500 and Dow Jones posted strong overall gains.
⚠️ Corteva underperformed relative to its agricultural sector peers.
🗓️ This marked the second consecutive day of stock gains.
📈 Corteva Inc. (CTVA) shares rose 2.07% to close at $81.01 on Thursday.
📊 The stock market saw a strong overall performance with the S&P 500 rising 1.02% and the Dow Jones up 1.62%.
⚠️ Despite positive daily movement, CTVA underperformed relative to its agricultural sector peers during this session.
🗓️ This marked the second consecutive day of gains for Corteva's stock price.
📅 The article was published on April 30, 2026, reflecting market data at that time.
Bullish Signals
Shares of Corteva Inc. (CTVA) rallied 2.07% to $81.01, demonstrating continued bullish momentum despite underperforming some competitors.
This marked the stock's second consecutive day of gains, highlighting sustained positive investor sentiment.
The rally occurred alongside strong market breadth, with the S&P 500 rising 1.02% and the Dow Jones Industrial Average advancing 1.62%, creating a favorable trading environment.
Risk Factors
Corteva Inc. (CTVA) underperformed relative to its competitors on Thursday despite recording a 2.07% gain to $81.01, while broader market indices like the S&P 500 and Dow Jones also rallied.
The stock's ability to match peer performance has wavered during an otherwise strong trading session, potentially signaling relative weakness in investor sentiment.
Corteva Inc. (CTVA) is currently trading at $79.63, representing a modest discount to a narrative fair value estimate of approximately $84.33. While the stock has experienced mixed short-term performance with declines over the past day, week, and month, it maintains a stronger longer-term trend showing an 11.1% return over the last 90 days and a 30.3% total shareholder return over the past year. This divergence between recent pullback and long-term gains suggests shifting market sentiment regarding the company's growth profile and risk characteristics as of April 24, 2026.
The core narrative supporting the potential upside hinges on Corteva's innovation pipeline, including premium trait launches like Vorceed and PowerCore, an expansion of biological products, and advancements in gene editing which enable secure market share and improved product mix. These factors are expected to translate into higher gross margins and earnings growth, while favorable policy shifts in gene editing and biofuels position the company for outsized long-term growth in sustainable agricultural inputs. However, this valuation story relies heavily on assumptions that crop protection pricing pressure and currency fluctuations will not erode the margin path anticipated by analysts.
Despite the "modestly undervalued" sentiment derived from the price-to-fair-value gap, valuation metrics present conflicting signals. Corteva trades at a P/E ratio of approximately 44.8x, which is significantly higher than the industry average of 29.6x, the peer average of 20x, and even its own calculated fair P/E multiple of 27.1x. This high valuation multiple raises clear concerns about the sustainability of future earnings relative to current costs, creating a tension between the optimistic growth trajectory implied by the fundamental analysis and the expensive multiple required to justify the stock price. Investors are advised to weigh these trade-offs between the promising earnings path and the elevated valuation risk before making decisions.
Ultimately, the article presents Corteva as a company with strong long-term catalysts that may currently be undervalued based on intrinsic growth models, yet simultaneously overvalued when judged against standard industry multiples. The investment case depends on whether the market's optimism regarding future revenue expansion and margin improvements can offset the current pricing pressures and currency risks that could derail the earnings path. The analysis suggests that while there is a theoretical upside to reach the $84.33 fair value, the high P/E ratio indicates that any disappointment in earnings growth or increased cost pressures could lead to significant volatility given the stock's premium valuation multiple.
💲 Shares trade at a modest discount to estimated fair value.
🌱 Future earnings growth driven by innovation and regulatory tailwinds.
⚠️ Margin risks from pricing pressure and currency fluctuations exist.
🎯 High valuation creates tension between strong prospects and expensive pricing.
📉 Corteva (CTVA) shares recently declined 1.9% over the past week and 1.2% over the past month despite a stronger 11.1% return over 90 days.
💲 The stock is currently trading at $79.63, which represents a modest discount to its estimated fair value of $84.33 (a 5.6% undervaluation).
🌱 Positive long-term growth narratives include advancements in innovation pipelines like premium trait launches and the expansion of biological products through gene editing.
💰 These innovations are expected to enable premium pricing, secure market share, improve product mix, and translate into higher gross margins and earnings growth.
⚖️ Regulatory shifts favoring sustainable agricultural inputs and biofuels could position Corteva for outsized revenue growth over the long term.
⚠️ Analysts warn that Crop Protection pricing pressure and currency swings could erode the margin and earnings path relied upon by forecasts.
📊 The P/E ratio presents a conflicting signal with the current 44.8x earnings, which is significantly higher than the 29.6x industry average and 20x peer average.
🎯 This high valuation multiple raises clear valuation risk, creating tension between the attractive earnings path story and expensive pricing relative to peers.
🔍 Investors must weigh whether the earnings growth narrative justifies the premium valuation or if the market is already pricing in future success.
🛡️ The article suggests scanning for undervalued quality companies as a strategy before the broader market catches on to similar investment opportunities.
Bullish Signals
Corteva has demonstrated a strong long-term trend with an 11.1% return over the past 90 days and a 30.3% one-year total shareholder return.
The stock is currently trading at $79.63, representing a modest undervaluation against a calculated narrative fair value of approximately $84.33 (5.6% discount).
Advancements in innovation including the premium trait launches of Vorceed and PowerCore are enabling higher gross margins and sustainable earnings growth.
Expansion of biological products and gene editing capabilities positions Corteva for outsized long-term growth as consumer preferences shift toward eco-friendly agricultural inputs.
Favorable policy shifts in gene editing and biofuels support accelerated adoption of sustainable solutions, potentially expanding both revenue and the addressable market.
Risk Factors
Corteva's recent share performance is negative, showing a 1.9% decline over the past week and a 1.2% decline over the past month.
Despite being framed as undervalued, the stock trades at a high P/E ratio of approximately 44.8x earnings compared to a 20x peer average and a 27.1x fair ratio, signaling clear valuation risk.
The optimistic growth narrative is contingent on avoiding margin erosion from crop protection pricing pressure and negative currency swings.
Analyst forecasts assume the success of specific innovation pipelines like Vorceed and PowerCore, creating concentration risk if these launches fail to gain traction.
Corteva Inc. has officially announced the executive leadership team responsible for leading its spin-off entity, "New Corteva," a publicly-traded crop protection company set to separate in the fourth quarter of 2026. The announcement builds upon a previous disclosure naming Luke Kissam, currently CEO of Albemarle, as the future chief executive officer who will join on June 1. Kissam joins an inaugural leadership slate designed to drive the new entity through innovation and operational efficiency, with Chair Greg Page serving a dual role as chairperson for both the current Corteva and the successor company post-separation.
The newly appointed team includes Jeff Rudolph as chief financial officer, Brook Cunningham as chief commercial officer, Ralph Ford as chief integrated operations officer, Reza Rasoulpour as chief technology officer, and Jim Alcombright as chief digital and information officer. The roles of chief legal officer and chief people officer remain open for future recruitment. Additionally, current executive vice president Robert King will transition to a strategic advisor role to the incoming CEO starting July 1, ensuring stability during the separation process before leaving the company at the end of 2026.
Leadership from both Corteva Chair Greg Page and Corteva CEO Chuck Magro emphasized that the future business will be anchored in innovation, sustainability, and enterprise-wide operational excellence. The new entity aims to leverage its technological leadership in nature-inspired technologies to pursue attractive returns in differentiated markets. To showcase this new direction, the leadership team has scheduled an investor day for September 15 at the New York Stock Exchange, with further details expected soon.
🚀 New Corteva planned for Q4 2026 spin-off focused on innovation and assets-light growth.
👤 Luke Kissam appointed incoming CEO with Greg Page transitioning as Chair.
🧪 Jeff Rudolph, Brook Cunningham, and Reza Rasoulpour lead finance, sales, and tech.
🗓 Investor Day scheduled for Sept 15 at NYSE to discuss future vision.
📅 Corteva has officially announced the executive leadership team for "New Corteva," its planned publicly-traded crop protection subsidiary to be separated in Q4 2026.
💼 Luke Kissam, former Albemarle Chairman and CEO, will serve as the incoming New Corteva CEO effective June 1, joining the current company immediately.
🚀 The new entity is designed to be innovation-driven, asset-light, and focused on leveraging nature-inspired technologies for differentiated growth.
⚖️ Greg Page, current Chair of Corteva, will transition to chairing New Corteva after separation to lead the company from a position of strength.
💰 Chuck Magro, CEO of the parent Corteva, emphasizes that the new team is anchored in innovation, sustainability, and operational excellence.
💵 Jeff Rudolph will serve as Chief Financial Officer (CFO) for the separated crop protection business.
🤝 Brook Cunningham has been appointed as Chief Commercial Officer to drive sales and market strategy.
⚙️ Ralph Ford will lead operations as Chief Integrated Operations Officer to ensure efficiency across the portfolio.
🧬 Reza Rasoulpour will head innovation as Chief Technology Officer, managing the company's technological leadership.
📱 Jim Alcombright will oversee digital transformation as Chief Digital and Information Officer.
⚖️ The roles of Chief Legal Officer and Chief People Officer remain open with searches currently underway to fill these positions.
🤝 Robert King will transition from EVP of Crop Protection to a Strategic Advisor ensuring a smooth separation before leaving at the end of 2026.
📈 Management credited Robert King's tenure for solidifying global leadership in Biologicals and launching over 1,000 new products.
🗓️ The executive team will host an investor day event on September 15 at the New York Stock Exchange to discuss their vision.
⏳ The separation transaction is currently on track to complete in the fourth quarter of 2026.
Bullish Signals
New Corteva splits in Q4 2026 for innovation growth.
Luke Kissam named CEO starting June 1.
Levers tech leadership for nature-inspired solutions.
Team confident in leading from strength.
Key leaders confirmed for CFO and ops roles.
Robert King transitions to strategic advisor July 1.
History shows consistent industry outperformance.
Hosts investor day Sept 15 at NYSE.
Adopts asset-light model to boost margins.
Risk Factors
Separation delayed until Q4 2026, risking valuation re-rating for two years.
Key CLO and CPO roles remain vacant creating immediate uncertainty.
Executive Robert King departs in 2026 reducing leadership continuity.
China price shifts and energy pressures threaten margins before benefits materialize.
Bullish Signals
Corteva will separate into a new, publicly-traded 'New Corteva' crop protection company in the fourth quarter of 2026, positioning it for innovation-driven growth.
Luke Kissam has been named CEO of New Corteva starting June 1, bringing extensive leadership experience from his previous role as Chairman, President and CEO at Albemarle.
The new company will leverage its technological leadership to deliver nature-inspired technologies and pursue opportunities with attractive returns.
Management is confident the business will 'lead a critical industry from a position of strength' under the new focused executive team.
Jeff Rudolph, Brook Cunningham, Ralph Ford, Reza Rasoulpour, and Jim Alcombright are confirmed as key leaders for the CFO, Commercial, Operations, Technology, and Digital roles respectively.
Robert King will transition to a strategic advisor role effective July 1, ensuring a smooth separation and continued stability through Q4 2026.
Past financial performance under current leadership has 'consistently outperformed the industry,' demonstrating strong execution capability prior to the split.
The company plans to host an investor day on September 15 at the New York Stock Exchange, signaling a commitment to transparency and engaging capital markets post-separation.
New Corteva will operate with an asset-light model focused on enterprise-wide operational excellence to enhance margins and efficiency.
Risk Factors
The planned separation of 'New Corteva' is not expected to occur until the fourth quarter of 2026, delaying potential market valuation re-rating and restructuring benefits for over two years.
Key executive roles such as Chief Legal Officer and Chief People Officer remain vacant with ongoing searches, creating immediate organizational uncertainty and potential execution risks during the transition period.
Executive Robert King is departing the company in 2026 after serving as a strategic advisor, representing a loss of institutional leadership continuity following his significant tenure.
The new entity faces external headwinds from 'China Price Shifts' and 'Energy Pressures' that could erode margins and disrupt global agrochemical supply chains before any separation benefits materialize.
Zacks Investment Research advises investors to consider two major agriculture operations stocks, Archer-Daniels-Midland Co. (ADM) and Corteva Inc. (CTVA), as attractive opportunities despite broader industry headwinds like volatile commodity prices and rising operating costs. The analysts maintain a constructive long-term outlook for the sector, citing innovation in seeds, crop inputs, and consumer preference shifts toward healthy, sustainable food products as key growth drivers. Currently, the agriculture operations industry is ranked within the top 23% of Zacks industries, suggesting an expectation of outperformance over the next three to six months, with both recommended stocks holding a favorable Zacks Rank of #1 or #2.
Archer-Daniels-Midland is highlighted for a rebound in its Nutrition segment and traction in Human Nutrition, specifically within the Flavors portfolio which benefits from solid North American demand and improved margins. The company is executing on its Optimize, Drive, and Grow pillars to enhance productivity and leverage digital tools for margin expansion. Zacks analysts project an expected revenue growth rate of 5% and an earnings growth rate of 26% for the current year, noting that the Zacks Consensus Estimate for ADM has improved by 9.4% over the last 30 days.
Corteva Inc. is recommended for its ability to drive above-market growth through an industry-leading product pipeline and rigorous operational discipline, operating via its Seed and Crop Protection segments. The company plans to accelerate innovation to meet demand for naturally derived products through three new collaboration agreements and aims to strengthen performance through strong price execution and supply-chain flexibility. Expected revenue and earnings growth rates for Corteva are projected at 4% and 8.7%, respectively, with the Zacks Consensus Estimate improving by 1.4% in the last 30 days. The article includes a disclaimer that the content is provided by third parties and has not been reviewed by The Globe and Mail.
🌾 Agriculture faces high costs but retains a constructive long-term outlook through innovation.
📈 Industry ranks in top 23%, signaling potential outperformance over the next three to six months.
💼 Two top stocks, ADM and Corteva, carry favorable Zacks Ranks of #1 or #2.
🚀 ADM projects 5% revenue and 26% earnings growth driven by nutrition segment recovery.
🌱 Corteva targets 4-8.7% growth via leading pipelines and new innovation collaborations.
🌾 The agriculture operations industry faces structural challenges like volatile commodity prices, high input costs, and rising operating expenses.
⚠️ Despite current headwinds, the sector's long-term outlook remains constructive due to innovation in seeds, crop inputs, and supply chains.
📈 The Zacks-defined Agriculture – Operations industry ranks in the top 23% of all industries, suggesting it will outperform the market over the next three to six months.
🏢 Two recommended stocks are Archer-Daniels-Midland (ADM) and Corteva Inc. (CTVA), both carrying a favorable Zacks Rank of #1 or #2.
🔍 ADM is benefiting from a rebound in its Nutrition segment, with Flavors portfolio gaining traction due to North American demand and improved margins.
💡 Archer-Daniels-Midland is advancing its Optimize, Drive, and Grow pillars to enhance productivity, cut costs, and expand BioSolutions using digital tools.
📊 ADM expects a 5% revenue growth and 26% earnings growth for the current year, with Zacks Consensus Estimate improving by 9.4% recently.
🌱 Corteva is positioned to drive above-market growth through its industry-leading product pipeline and rigorous approach to innovation.
🤝 Corteva aims to meet demand for naturally derived products via three new collaboration agreements focused on accelerating innovation.
📉 Corteva expects a 4% revenue growth and an 8.7% earnings growth for the current year, with Zacks Consensus Estimate improving by 1.4%.
⚠️ Note: The article text contains unrelated promotional content regarding a semiconductor company that should be ignored for this agriculture-focused summary.
Bullish Signals
ADM Nutrition rebounds with strong demand and improved margins.
ADM drives productivity, cost savings, and margin via digital tools.
ADM expects 5% revenue growth and 26% earnings growth this year.
CTVA drives above-market growth via a leading product pipeline.
CTeva benefits from strong execution and flexible supply chain.
CTVA expects 4% revenue growth and 8.7% earnings growth.
Both stocks hold favorable Zacks Ranks to outperform the market.
Risk Factors
Volatile prices and high costs squeeze agriculture margins.
ADM struggles with headwinds despite Nutrition segment gains.
Corteva sees only modest 4% revenue and 8.7% earnings growth.
Bullish Signals
Archer-Daniels-Midland (ADM) is benefiting from a rebound in its Nutrition segment, with the Flavors portfolio gaining traction due to solid North American demand, international customer wins, and improved margins.
ADM continues to advance its Optimize, Drive and Grow pillars, enhancing productivity, accelerating cost savings, and leveraging digital tools to unlock margin opportunities.
Archer-Daniels-Midland is expected to have a revenue growth rate of 5% and an earnings growth rate of 26% for the current year, with the Zacks Consensus Estimate for earnings improving 9.4% over the last 30 days.
Corteva (CTVA) is poised to drive above-market growth through its industry-leading product pipeline, rigorous innovation approach, and operating discipline.
Strong price execution in seed, supply-chain flexibility, and solid market demand for Corteva's balanced new product portfolios are driving its performance.
Corteva is expected to have a revenue growth rate of 4% and an earnings growth rate of 8.7% for the current year, with the Zacks Consensus Estimate for earnings improving 1.4% over the last 30 days.
Both Archer-Daniels-Midland and Corteva currently carry favorable Zacks Ranks (#1 Strong Buy or #2 Buy), positioning them to outperform the market.
Risk Factors
The agriculture operations industry faces structural challenges including volatile commodity prices, elevated input and labor costs, trade-related uncertainty, and rising operating expenses.
Industry margins are compressed due to these cost pressures, testing the long-term sustainability of profitability.
Archer-Daniels-Midland (ADM) is facing headwinds despite its Nutrition segment rebound, as it continues to manage productivity and innovation in a difficult environment.
Corteva (CTVA) is expected to grow revenue by only 4% and earnings by 8.7% for the current year, indicating modest growth potential amidst broader sector challenges.
Shares of Corteva, Inc. (CTVA) have recently reached a new 52-week high of $85.63, marking an impressive outperformance against broader market indices with the stock up 11.8% over the past month and 27.3% year-to-date compared to sector averages. The company has demonstrated strong recent earnings momentum, beating the Zacks Consensus Estimate in each of the last four quarters, including reporting EPS of $0.22 versus a consensus estimate of $0.21 in its most recent earnings report on February 3, 2026. For the current fiscal year, analysts expect Corteva to post earnings of $3.63 per share on revenues of $18.09 billion, while next fiscal year projections stand at $3.99 per share on $18.76 billion in revenues, representing anticipated growth rates of 8.68% and 9.81%, respectively.
Despite the positive momentum, valuation metrics present a mixed picture for investors assessing the company's future trajectory. Corteva currently trades at 23.5X current fiscal year EPS estimates and 16.6X trailing cash flow basis, figures that significantly exceed the peer industry averages of 14.4X and 8X, respectively. The stock holds a PEG ratio of 2.91 and carries a Zacks Style Score combination (VGM) of B based on individual Value (C), Growth (B), and Momentum (B) scores. However, the company maintains a Zacks Rank of #2 (Buy), which is bolstered by a solid earnings estimate revision trend and aligns with investment criteria for stocks carrying Ranks of 1 or 2 alongside Style Scores of A or B.
In addition to Corteva's individual fundamentals, the broader Agriculture - Operations industry remains in the top 29% across the Zacks universe, suggesting positive tailwinds for holdings like Archer Daniels Midland Company (ADM). ADM currently boasts a Zacks Rank of #1 (Strong Buy) with Value and Momentum scores of B and Growth score of D, supported by recent earnings that beat consensus estimates by 4.82%. The company is projected to earn $4.32 per share on $84.27 billion in revenue for the current fiscal year, trading at a forward P/E of 16.71X and P/CF of 12.2X, having gained 4% over the past month. While Corteva appears to remain a viable investment option with potential for further growth, investors should consider its relative valuation premiums compared to industry peers alongside the favorable positioning of the broader agricultural sector.
📈 Corteva stock surged 11.8% monthly to a new 52-week high of $85.63.
🏆 Company beat earnings estimates for four consecutive quarters with consistent positive revisions.
🎯 Analysts forecast $3.63 EPS and $18.09B revenue for the current year.
⚠️ Valuation at 23.5X forward P/E suggests premium pricing over industry peers.
📈 Corteva, Inc. stock rose 11.8% over the past month and reached a new 52-week high of $85.63.
🏆 The company has beaten earnings estimates for four consecutive quarters, including an EPS of $0.22 in February 2026.
📊 Analysts forecast current year earnings of $3.63 per share on revenues of $18.09 billion.
💰 Next year's expected earnings are projected at $3.99 per share with revenues of $18.76 billion.
🎯 Corteva holds a Zacks Rank of #2 (Buy) driven by positive earnings estimate revisions.
📐 Valuation metrics show the stock trades at 23.5X forward EPS and 16.6X trailing cash flow.
🧠 Style Scores indicate a C for Value, B for Growth, and B for Momentum, resulting in a VGM Score of B.
🌾 The Agriculture - Operations industry is currently positioned in the top 29% of all tracked industries.
➡️ Peer company Archer Daniels Midland Company (ADM) is also rated with a Zacks Rank #1 (Strong Buy).
💹 ADM stock has gained 4% recently and trades at a forward P/E of 16.71X.
📉 Corteva's Value Score of C suggests the stock trades at a premium compared to industry peers at 14.4X.
⚠️ Investors are encouraged to evaluate whether the current valuation has outpaced the company's fundamentals.
🛒 A combined Zacks Rank and Style Scores approach is recommended for selecting stocks with growth potential.
📄 This analysis was originally published on Zacks Investment Research and highlights free stock reports available.
Bullish Signals
Shares up 11.8% in past month.
Stock hit new 52-week high of $85.63.
Gained 27.3% since start of year.
Beat consensus estimates for last four quarters.
Expected EPS $3.63 on revenues $18.09B.
Next year EPS $3.99 on $18.76B revenues.
Zacks Rank #2 Buy with solid estimate revisions.
VGM Score B with strong growth and momentum.
Agriculture industry in top 29% of all industries.
Peer ADM ranks #1 Strong Buy.
Risk Factors
Valuation premium at 23.5X forward EPS vs 14.4X peers signals overvaluation.
Trailing cash flow multiple of 16.6X exceeds peers' 8X average.
High PEG ratio of 2.91 suggests optimistic growth expectations.
Four consecutive earnings beats lack structural change support.
Value Score of C trails higher-rated peer Archer Daniels Midland.
Modest industry revenue growth of only 3.98% limits tailwinds.
High valuation caps upside if sentiment shifts or peers outperform.
Bullish Signals
Shares of Corteva, Inc. (CTVA) have been strong performers lately, up 11.8% over the past month.
The stock hit a new 52-week high of $85.63 in the previous session and has gained 27.3% since the start of the year.
Corteva, Inc. has beaten the Zacks Consensus Estimate in each of the last four quarters, demonstrating consistent earnings surprises.
For the current fiscal year, the company is expected to post EPS of $3.63 per share on revenues of $18.09 billion.
For the next fiscal year, Corteva, Inc. is expected to earn $3.99 per share on $18.76 in revenues, representing a 9.81% year-over-year change.
The stock carries a Zacks Rank of #2 (Buy) thanks to a solid earnings estimate revision trend.
Corteva, Inc. has a VGM Score of B with Growth and Momentum Scores of B, indicating strong growth and momentum characteristics.
The Agriculture - Operations industry is in the top 29% of all industries tracked, providing favorable tailwinds for CTVA.
Analyst peer Archer Daniels Midland Company (ADM) also shows strength with a Zacks Rank of #1 (Strong Buy) and recent earnings that beat consensus estimates by 4.82%.
Risk Factors
Corteva, Inc. trades at a premium valuation of 23.5X forward EPS estimates compared to the peer industry average of 14.4X, suggesting the stock may be overvalued relative to competitors.
On a trailing cash flow basis, Corteva is valued at 16.6X versus its peer group's average of 8X, indicating a significant pricing disadvantage for value-oriented investors.
The stock carries a PEG ratio of 2.91, which is high and suggests that current growth expectations are not fully priced in or may be optimistic given the valuation level.
While positive earnings surprises have occurred recently, relying on four consecutive beats without underlying structural change creates sustainability risks as estimates likely tighten over time.
The company's Value Score of C indicates that it falls short on value metrics compared to higher-rated peers like Archer Daniels Midland Company, which holds a B-grade Value Score.
Industry tailwinds may not persist indefinitely if the Agriculture - Operations industry growth rate slows, as current projections show modest revenue growth of only 3.98% for the current fiscal year.
Corteva's high valuation relative to peers limits potential upside if market sentiment shifts or if competitor earnings outperform without a corresponding stock price move.
Corteva Agriscience and the Puerto Rico science museum, EcoExploratorio, have partnered to expand their PR STEM Series initiative aimed at engaging young people in agricultural science, technology, engineering, and math. Under this expanded partnership, 20 students enrolled in grades six through eight are participating in a multisession educational program designed to provide hands-on experiences. The curriculum includes workshops, STEM activities, and an immersive visit to Corteva’s facilities located in Puerto Rico, giving participants direct exposure to the agricultural biotechnology sector.
The program focuses on introducing students to scientific research, innovation, and their potential roles in food security and sustainability efforts. Participants will meet with science professionals and learn about agricultural research while exploring academic pathways and career opportunities within modern science and agriculture. Luis Colón, community relations manager for Corteva Agriscience in Puerto Rico, stated that the company views education as a catalyst for social transformation, aiming to provide first-hand exposure to agricultural biotechnology and inspire future scientists in Puerto Rico.
EcoExploratorio, which leads the PR STEM Series, emphasized its commitment to strengthening interest in science careers by connecting classroom learning with industry work and research. Jenny M. Guevara, executive director of EcoExploratorio Inc., affirmed that the collaboration reaffirms their dedication to transforming science education in Puerto Rico. The initiative ultimately seeks to inspire new generations of scientists specifically within the fields of agricultural biotechnology and innovation through these structured educational experiences.
🤝 Corteva and EcoExploratorio partner to expand Puerto Rico STEM Series program for students.
👥 Twenty sixth-to-eighth graders participate in workshops, facility visits, and immersive experiences.
🌾 Participants explore agricultural biotechnology, research careers, and food security through industry connections.
🌱 Corteva Agriscience and EcoExploratorio have partnered to expand the Puerto Rico STEM Series program.
👥 Twenty students in grades six through eight are participating in the current multisession initiative.
📚 The curriculum includes workshops, STEM activities, and immersive experiences such as a visit to Corteva’s Puerto Rico facilities.
🌾 Students will gain exposure to agricultural biotechnology, scientific research, and food security initiatives.
💼 Participants will meet science professionals and explore career paths in modern agriculture and science.
🤝 Luis Colón of Corteva stated that the partnership aims to inspire the future scientists of Puerto Rico.
🔬 The program connects classroom learning with industry work, research, and innovation opportunities.
📣 Jenny M. Guevara of EcoExploratorio reaffirmed their commitment to transforming science education in the region.
Bullish Signals
Corteva and EcoExploratorio partner to expand Puerto Rico STEM education support.
20 students in grades six-eight join a comprehensive workshop program.
Students visit Corteva facilities for biotechnology and research exposure.
Program reinforces STEM interest through food security and sustainability topics.
Collaboration inspires the next generation of agricultural biotechnology scientists.
Risk Factors
Release lacks financial data or risk disclosures.
No info on market competition or Puerto Rico risks.
Bullish Signals
Corteva Agriscience and EcoExploratorio have partnered to expand their commitment to Puerto Rico STEM education, demonstrating strong support for local science careers.
Under the new partnership initiative, 20 students in grades six through eight are now participating in a comprehensive multisession program featuring workshops and immersive experiences.
Students are gaining valuable exposure to agricultural biotechnology and scientific research by visiting Corteva's facilities in Puerto Rico, connecting classroom learning directly with industry innovation.
The program reinforces interest in STEM careers by introducing young people to food security, sustainability efforts, and diverse career paths tied to modern agriculture.
EcoExploratorio reaffirmed its dedication to transforming science education through this collaboration, aiming to inspire the next generation of agricultural biotechnology scientists.
Risk Factors
The news release contains only positive community engagement initiatives and lacks any mention of financial performance, earnings, or operational risks.
There is no information provided regarding market competition, regulatory challenges, or potential headwinds facing Corteva Agriscience in the Puerto Rico market.
The article compares Adecoagro (AGRO) and Corteva, Inc. (CTVA) within the Agriculture-Operations sector to determine which offers better value to investors. Zacks Investment Research utilizes its proprietary Style Scores system combined with Zacks Rank to evaluate these companies. Adecoagro currently holds a Zacks Rank of #2 (Buy), while Corteva has a Zacks Rank of #3 (Hold). This ranking reflects that AGRO's earnings estimate revisions have been more impressive, indicating a stronger improving analyst outlook compared to CTVA. In terms of valuation metrics, AGRO demonstrates significantly more attractive figures; it carries a forward P/E ratio of 10.99 and a PEG ratio of 0.31, whereas CTVA has a forward P/E of 23.54 and a PEG ratio of 2.92.
Further supporting AGRO's valuation profile is its Price-to-Book (P/B) ratio, which stands at 0.85 compared to CTVA's 2.37. The P/B ratio measures a stock's market value relative to its book value, defined as total assets minus total liabilities. Based on these combined metrics and additional fundamentals, AGRO is awarded a Value grade of A by the Style Scores system, while CTVA receives a Value grade of C. Consequently, the analysis concludes that AGRO stands above CTVA due to its solid earnings outlook and superior valuation figures, making it the recommended choice for value investors seeking undervalued opportunities at current share price levels.
The text also notes an update or separate analysis where Adecoagro (AGRO) is highlighted as holding a Zacks Rank of #1 (Strong Buy) alongside its Value grade of A. In this context, AGRO's P/E ratio is cited as 12.43 against an industry average of 15.81, and its forward P/E has ranged between 5.76 and 14.40 over the past year with a median of 9.05. Additionally, the P/B ratio for AGRO is listed at 0.56, which is notably attractive compared to its industry average of 1.24. The historical range for AGRO's P/B ratio includes highs of 0.86 and lows of 0.56 with a median of 0.71. These data points reinforce the assertion that Adecoagro is likely undervalued relative to both Corteva and its own industry peers, positioning it as one of the market's strongest value stocks for those utilizing fundamental analysis and ranking systems.
🌾 Adecoagro and Corteva operate in ag but show significant value differences.
📈 AGRO holds a #1 Strong Buy rank versus CTVA's #3 Hold rank.
💵 AGRO trades at low P/E (0.85 P/B) while CTVA is premium valued.
⚠ AGRO's Value score is an A grade compared to CTVA's C rating.
🌾 Both Adecoagro (AGRO) and Corteva Inc. (CTVA) operate within the Agriculture - Operations sector, but their value profiles differ significantly.
📊 Zacks Investment Research rates AGRO with a #2 Buy rank compared to CTVA's #3 Hold rank based on earnings estimate revisions.
💵 AGRO commands a forward P/E ratio of 10.99, which is notably lower than CTVA's forward P/E of 23.54.
📉 The Price-to-Earnings-to-Growth (PEG) ratio shows AGRO at 0.31 versus CTVA's 2.92, indicating better growth compensation for price in AGRO.
🏦 Adecoagro trades at a P/B ratio of 0.85 compared to Corteva's 2.37, suggesting AGRO is priced below its book value while CTVA is not.
🏆 The Style Scores Value category grades AGRO an A while assigning CTVA a C based on fundamental valuation metrics.
📈 Agrostis Holdings (AGRO) holds an updated Zacks Rank of #1 Strong Buy and maintains its Value grade of A in recent analysis.
🔄 Adecoagro's forward P/E has historically ranged between 5.76 and 14.40 with a median of 9.05, positioning current valuations attractively.
📉 The industry average P/E is 15.81 while AGRO's current P/E is 12.43, showing it trades below its peer sector average.
🏛 Adecoagro's P/B ratio of 0.56 is significantly lower than the industry median of 0.71 and low point of 0.56 seen over the past year.
💰 Zacks analysis concludes AGRO is the superior value option due to its strong earnings outlook and favorable valuation figures.
📉 Value investing strategies prioritize undervalued stocks with high Zacks Ranks and A+ grades in specific style categories like Value.
Bullish Signals
Adecoagro holds a Zacks Rank #1, the highest for earnings revisions.
AGRO receives a Value grade A with forward P/E below industry average.
The stock trades at 0.56 book value discount vs industry median of 1.24.
Analyst expectations keep AGRO classified as one of market's strongest value stocks.
Risk Factors
CTVA has weaker analyst rankings (Zacks #3) than AGRO (#1-2).
CTVA trades at higher forward P/E (23.54) versus AGRO (10.99).
CTVA's PEG ratio of 2.92 exceeds AGRO's 0.31, suggesting overvaluation.
CTVA received Value grade C compared to AGRO's A.
CTVA's P/B ratio of 2.37 surpasses AGRO's 0.85 and industry average.
CTVA lacks value appeal due to low Zacks rank and Value grade.
Bullish Signals
Adecoagro (AGRO) has a Zacks Rank #1 (Strong Buy), representing the highest possible ranking for earnings estimate revisions.
AGRO holds a Value grade of A based on its impressive valuation metrics, including a forward P/E ratio that trades below the industry average of 15.81.
The stock currently trades at a book value discount with a P/B ratio of 0.56, significantly lower than its industry median of 1.24.
Analysts' expectations for AGRO's earnings remain strong, supporting its classification as one of the market's strongest value stocks.
Corteva (CTVA) has a Zacks Rank of #3 (Hold), indicating that its earnings estimate revision activity has been less impressive than Adecoagro.
Risk Factors
CTVA holds a Zacks Rank of #3 (Hold) compared to AGRO's #1 or #2 rankings, indicating weaker earnings estimate revision activity and analyst outlook.
CTVA trades at a forward P/E of 23.54 versus AGRO's 10.99, signaling that the market values CTVA at a significantly higher multiple.
CTVA has a PEG ratio of 2.92 compared to AGRO's 0.31, suggesting its expected earnings growth does not justify its current valuation.
CTVA received a Value grade of C while AGRO holds an A, indicating fundamental metrics suggest CTVA is overvalued relative to peers.
CTVA's P/B ratio of 2.37 is substantially higher than AGRO's 0.85 or industry average, implying market value significantly exceeds book value.
CTVA's Value grade of C and lack of strong Zacks Rank support make it less attractive to value-oriented investors compared to AGRO.
Over the past year, insiders at Corteva Inc. (NYSE:CTVA) have predominantly sold shares rather than purchasing them, a trend that analysts from Simply Wall St are interpreting as a potential sign of caution among company leadership. The most significant transaction occurred when Senior VP & Strategic Advisor Cornel Fuerer sold US$2.6m worth of shares at a price of US$68.06 each, which was slightly below the current share price of US$85.46. This sale represented only 27% of Fuerer's total holdings, and since no insider purchases were recorded during the same period, the lack of confidence from management is noted by investors who typically prefer to see buying activity as a stronger positive signal than selling.
Beyond the largest single transaction, other notable insiders also reduced their stakes within the last three months. Specifically, VP, Controller & Principal Accounting Officer Brian Titus sold US$306k worth of shares during this timeframe, with no accompanying purchases recorded for either executive or others in that window. While insider ownership remains relatively high at approximately 0.1% of the company, which translates to holdings valued around US$66m, the combination of significant selling activity and a lack of new insider investments has led the analysis team to advise practice some caution before buying the stock. The report emphasizes that while insiders own a substantial amount to indicate some alignment with shareholders, they currently do not own a "heap" of shares and have been selling rather than accumulating.
The article concludes by contextualizing these internal transactions alongside external market data and risk factors associated with Corteva. Simply Wall St notes that despite the company generating money and showing profit growth, investors should remain wary as insiders have not provided any comfort signals through buying over the last year. Additionally, the analysis highlights one specific warning sign present in the company's financial profile that shareholders should be aware of before making investment decisions. The editorial team reminds readers that this commentary is based on historical data and analyst forecasts, does not constitute financial advice, and does not account for the latest price-sensitive announcements or individual investor situations.
📉 Insiders sold US$3.9M in shares last year with no purchases recorded.
💼 Senior VP Cornel Fuerer sold $2.6M of stock at a discount to market price.
⚠️ Significant selling activity combined with low ownership warrants investment caution for Corteva.
📉 Corteva (CTVA) insiders sold US$3.9 million of shares over the past year, signaling potential market hesitation.
💼 Senior VP & Strategic Advisor Cornel Fuerer executed the largest single insider sale of US$2.6 million at $68.06 per share.
⚠️ The sale price of $68.06 was below the current stock price of $85.46, which insiders selling at a discount often implies negative valuation views.
🛑 No insiders purchased any Corteva shares during the last 12 months, resulting in a net reduction of company ownership by leadership.
📊 Significant insider selling occurred over the last three months, including US$306k sold by VP Brian Titus with zero purchases recorded.
💰 Current insider holdings total approximately US$66 million, representing 0.1% of the company but indicating moderate alignment.
⚖️ While Corteva is profitable and growing profits, the combination of selling activity and low insider ownership warrants investment caution.
📈 The article notes a single warning sign regarding Corteva that investors should be aware of before making a purchase decision.
🔎 Analysis suggests investors should investigate further if numerous insiders are simultaneously selling their holdings rather than buying.
Bullish Signals
Corteva insiders own 0.1%, worth ~US$66M.
High alignment between management and small shareholders.
Risk Factors
Insiders sold $3.9m with zero purchases, signaling hesitation.
Senior VP sold $2.6m at $68 vs current $85 price.
VP Titus sold $306k in 3 months amid no buying.
Only 0.1% insider ownership shows low alignment.
Article warns against buying due to insider selling.
Bullish Signals
Corteva insiders own 0.1% of the company, which is worth about US$66 million.
This level of insider ownership indicates some alignment between management and smaller shareholders.
Risk Factors
Corteva insiders sold US$3.9m of shares over the past year without recording any purchases, suggesting hesitation among leadership.
Senior VP & Strategic Advisor Cornel Fuerer executed a significant sale of US$2.6m worth of shares at US$68.06, which was below the current price of US$85.46, implying insiders may view the valuation as fully priced or lower.
Over the last three months, VP Brian Titus sold an additional US$306k in shares while no purchases were recorded, increasing caution around the stock.
Corteva insiders own only 0.1% of the company, which indicates a relatively low level of ownership alignment compared to some peers.
The article explicitly warns that Corteva may not be the best stock to buy and suggests practicing caution before investing due to insider selling activity.
Bereneg Bank maintained its Hold rating on Corteva (CTVA) yesterday, setting a price target of $78.00 following the company's earnings release for the quarter ending December 31. According to the article, the company reported quarterly revenue of $3.91 billion and a GAAP net loss of $552 million, a significant decrease from last year's figures which showed revenue of $3.98 billion and a GAAP net loss of $41 million. Currently, the analyst consensus on Corteva is a Moderate Buy with an average price target of $84.18, representing 1.75% upside from its share price which closed at $82.73.
The analysis highlights mixed market sentiment surrounding Corteva's stock following the earnings report. While Berenberg maintains a Hold rating, TipRanks noted that another analyst firm also downgraded the stock to Hold with an $88.00 price target. Corporate insider activity further reflects negative sentiment on the stock, with 69 insiders showing selling behavior over the past quarter compared to earlier this year. Notably, last month, BRIAN TITUS, the VP, Controller and Principal Accounting Officer of CTVA, sold 8,311 shares for a total value of $636,170.16.
The broader analyst landscape presents conflicting outlooks, with several major firms adjusting their positions on Corteva recently. Notable adjustments include Citi raising its price target to $83 from $80, Mizuho increasing its target to $82 from $80, while other institutions moved to downgrade ratings or adjust views. UBS downgraded Corteva from Buy to Neutral, BWG Global changed the view from Positive to Mixed, and Oracle also received upgrades and downgrades from top Wall Street analysts. Despite these conflicting signals, the average price target remains above current trading levels, suggesting moderate bullishness overall despite the Hold rating maintained by Berenberg Bank.
📉 Berenberg Bank maintains Hold rating with $78 price target below closing price of $82.73.
⚠ GAAP net loss widened to $552 million compared to $41 million prior year quarter.
📊 Market consensus Moderate Buy at $84.18 despite insider selling by 69 executives.
📉 Berenberg Bank maintained a Hold rating on Corteva (CTVA) with a new price target of $78.00.
💰 Corteva's shares closed yesterday at $82.73, above the analyst's price target.
📊 The current market consensus for CTVA is a Moderate Buy with an average price target of $84.18.
🤖 TipRanks recently downgraded its own view on the stock to Hold with an $88.00 price target.
💸 Corteva reported quarterly revenue of $3.91 billion for the quarter ending December 31, a slight decline from last year's $3.98 billion.
⚠️ The company posted a GAAP net loss of $552 million compared to a loss of $41 million in the same period last year.
📉 Corporate insider sentiment is negative with increased share selling by 69 insiders over the past quarter.
👤 VP Brian Titus recently sold 8,311 shares totaling $636,170.16 for the Controller and Principal Accounting Officer role.
💬 Other analysts have made recent changes, including Citi raising its price target to $83 and Mizuho to $82.
📉 UBS downgraded its view on Corteva from Buy to Neutral in recent market updates.
Bullish Signals
Hold Rating Maintained at Bereneng Bank with Price Target of $78.00.
Analyst Consensus is Moderate Buy at Average Price Target of $84.18.
Citi Raised Corteva Price Target to $83 from $80, Reflecting Confidence.
Mizuho Increased Corteva Price Target to $82 from $80, Bullish Adjustment.
Risk Factors
Bereneg Bank rates Corteva Hold below $82.73 stock price.
Analyst consensus downgraded to Moderate Buy with $84.18 target.
TipRanks downgraded Anthropic hold with $88.00 price target.
Quarterly GAAP net loss hit $552 million, up from $41M.
Revenue declined to $3.91 billion from $3.98 billion last year.
Corporate insiders negative as selling activity increased in quarter.
VP sold 8,311 shares worth $636,170 signaling reduced confidence.
Bullish Signals
Bereneng Bank maintained a Hold rating with a price target of $78.00, indicating sustained analyst interest in the stock.
The current analyst consensus remains a Moderate Buy with an average price target of $84.18, suggesting positive market sentiment compared to individual analyst downgrades.
Citi raised Corteva's price target to $83 from $80, reflecting continued confidence in the company's outlook.
Mizuho also increased its price target for Corteva to $82 from $80, showing a bullish adjustment by another major bank.
The article highlights multiple price target increases alongside downgrades, suggesting a mixed but potentially stable investment case.
Risk Factors
Bereneg Bank maintains a Hold rating on Corteva (CTVA) with a price target of $78.00, which is below the current stock price of $82.73.
The analyst consensus has downgraded to Moderate Buy from an average price target of $84.18 representing only 1.75% upside potential.
TipRanks - Anthropic also downgraded the stock to a Hold with a lower price target of $88.00 compared to previous expectations.
Corteva reported a quarterly GAAP net loss of $552 million for the quarter ending December 31, a significant deterioration from last year's GAAP net loss of $41 million.
Despite current revenue of $3.91 billion, this is down from $3.98 billion reported last year, indicating declining revenue performance.
Corporate insider sentiment is negative with an increase in insider selling activity over the past quarter involving 69 insiders.
VP Brian Titus sold 8,311 shares worth $636,170.16 last month, signaling reduced confidence from top company officials.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)